A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.

• Status: Recruiting
• Trial end date: 2024-06-30

Summary

To observe the efficacy and safety of Ruxolitinib and Etoposide combined with DDGP regimen ( cis-Platinum, Dexamethasone, Gemcitabine and Pegaspargase) in the first-line induction therapy of T cell lymphoma and NK/T cell lymphoma-associated hemophagocytic syndrome.

• Phase: Phase 4

Details

• Lead Sponsor: Zhengzhou University
• Treatments: Cisplatin; Dexamethasone; Etoposide; Gemcitabine; Pegaspargase